

# Amira Guirguis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1559399/publications.pdf>

Version: 2024-02-01

46  
papers

1,209  
citations

430874

18  
h-index

414414

32  
g-index

49  
all docs

49  
docs citations

49  
times ranked

1056  
citing authors

#	ARTICLE	IF	CITATIONS
1	Knowledge and Use of Over-the-counter Drugs in Italy: An Exploratory Survey-based Study in the General Population. <i>Current Neuropharmacology</i> , 2023, 21, 133-141.	2.9	3
2	<i>In silico</i> studies on recreational drugs: 3D quantitative structure activity relationship prediction of classified and <i>de novo</i> designer benzodiazepines. <i>Chemical Biology and Drug Design</i> , 2023, 101, 40-51.	3.2	3
3	Assessing prevalence, knowledge and use of cognitive enhancers among university students in the United Arab Emirates: A quantitative study. <i>PLoS ONE</i> , 2022, 17, e0262704.	2.5	7
4	Misuse of Anticholinergic Medications: A Systematic Review. <i>Biomedicines</i> , 2022, 10, 355.	3.2	10
5	NPS detection in prison: A systematic literature review of use, drug form, and analytical approaches. <i>Drug Testing and Analysis</i> , 2022, 14, 1350-1367.	2.6	17
6	Benefits and Harms of "Smart Drugs" (Nootropics) in Healthy Individuals. <i>Drugs</i> , 2022, 82, 633-647.	10.9	17
7	Designer Benzodiazepines' Activity on Opioid Receptors: A Docking Study. <i>Current Pharmaceutical Design</i> , 2022, 28, 2639-2652.	1.9	3
8	A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases. <i>Pharmaceuticals</i> , 2022, 15, 565.	3.8	9
9	Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). <i>Pharmaceuticals</i> , 2022, 15, 675.	3.8	10
10	Beyond the "purple drank": Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports. <i>Journal of Psychopharmacology</i> , 2021, 35, 681-692.	4.0	21
11	The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review. <i>Brain Sciences</i> , 2021, 11, 355.	2.3	66
12	The e-psychoactive drugs' psychopharmacology. <i>Current Opinion in Pharmacology</i> , 2021, 57, 165-174.	3.5	14
13	Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants. <i>Frontiers in Psychiatry</i> , 2021, 12, 657397.	2.6	40
14	New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review. <i>Experimental Neurology</i> , 2021, 339, 113638.	4.1	29
15	New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature. <i>Medicina (Lithuania)</i> , 2021, 57, 580.	2.0	16
16	The Psychonauts' Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity. <i>Pharmaceuticals</i> , 2021, 14, 720.	3.8	6
17	COVID-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis. <i>Brain Sciences</i> , 2021, 11, 907.	2.3	11
18	Psychonauts' psychedelics: A systematic, multilingual, web-crawling exercise. <i>European Neuropsychopharmacology</i> , 2021, 49, 69-92.	0.7	13

#	ARTICLE	IF	CITATIONS
19	The clinical challenges of synthetic cathinones. British Journal of Clinical Pharmacology, 2020, 86, 410-419.	2.4	50
20	The Psychonauts™ World of Cognitive Enhancers. Frontiers in Psychiatry, 2020, 11, 546796.	2.6	24
21	Piloting the UK's First Home-Office-Licensed Pharmacist-Led Drug Checking Service at a Community Substance Misuse Service. Behavioral Sciences (Basel, Switzerland), 2020, 10, 121.	2.1	18
22	COVID-19: The Hidden Impact on Mental Health and Drug Addiction. Frontiers in Psychiatry, 2020, 11, 767.	2.6	101
23	Novel Opioids: Systematic Web Crawling Within the e-Psychonauts™ Scenario. Frontiers in Neuroscience, 2020, 14, 149.	2.8	24
24	Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database. Brain Sciences, 2020, 10, 105.	2.3	20
25	Exploring the Baseline Knowledge and Experience of Healthcare Professionals in the United Kingdom on Novel Psychoactive Substances. Brain Sciences, 2020, 10, 142.	2.3	9
26	How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe. British Journal of Clinical Pharmacology, 2020, 86, 452-481.	2.4	5
27	Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach. Frontiers in Psychiatry, 2020, 11, 632405.	2.6	24
28	Substance-Use Disorders and Violence. Comprehensive Approach To Psychiatry, 2020, , 95-114.	1.0	6
29	“New/Designer Benzodiazepines”™: An Analysis of the Literature and Psychonauts™ Trip Reports. Current Neuropharmacology, 2020, 18, 809-837.	2.9	51
30	The e-Psychonauts™ “Spiced”™ World; Assessment of the Synthetic Cannabinoids™ Information Available Online. Current Neuropharmacology, 2020, 18, 966-1051.	2.9	16
31	What About Drug Checking? Systematic Review and Netnographic Analysis of Social Media. Current Neuropharmacology, 2020, 18, 906-917.	2.9	9
32	The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review. Expert Review of Neurotherapeutics, 2019, 19, 1253-1264.	2.8	16
33	New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues. Current Addiction Reports, 2019, 6, 140-152.	3.4	7
34	An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. International Journal of Neuropsychopharmacology, 2019, 22, 270-277.	2.1	105
35	Assessing the 2004-2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems. Frontiers in Pharmacology, 2019, 10, 46.	3.5	58
36	Method development for the determination of elements in <i>Hypericum perforatum</i> L. (St John's) Tj ETQq0 0 0 rgBT /Overlock 10 T microwave digestion. Journal of Pharmacy and Pharmacology, 2018, 71, 38-45.	2.4	7

#	ARTICLE	IF	CITATIONS
37	Detection of newly emerging psychoactive substances using Raman spectroscopy and chemometrics. RSC Advances, 2018, 8, 31924-31933.	3.6	21
38	Exploration of the Use of New Psychoactive Substances by Individuals in Treatment for Substance Misuse in the UK. Brain Sciences, 2018, 8, 58.	2.3	20
39	Psychedelic Fauna for Psychonaut Hunters: A Mini-Review. Frontiers in Psychiatry, 2018, 9, 153.	2.6	10
40	Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. Brain Sciences, 2018, 8, 73.	2.3	56
41	Identification of new psychoactive substances (NPS) using handheld Raman spectroscopy employing both 785 and 1064 nm laser sources. Forensic Science International, 2017, 273, 113-123.	2.2	51
42	New psychoactive substances: a public health issue. International Journal of Pharmacy Practice, 2017, 25, 323-325.	0.6	18
43	Intended and unintended use of cathinone mixtures. Human Psychopharmacology, 2017, 32, e2598.	1.5	46
44	Drowning in diversity? A systematic way of clustering and selecting a representative set of new psychoactive substances. RSC Advances, 2017, 7, 53181-53191.	3.6	13
45	The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. Frontiers in Psychiatry, 2017, 8, 240.	2.6	75
46	Survey of knowledge of legal highs (novel psychoactive substances) amongst London pharmacists. Drugs and Alcohol Today, 2015, 15, 93-99.	0.7	49